Hudson Bay Capital Management LP Buys Shares of 650,000 Translational Development Acquisition Corp. (NASDAQ:TDACU)

Hudson Bay Capital Management LP bought a new position in shares of Translational Development Acquisition Corp. (NASDAQ:TDACUFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 650,000 shares of the company’s stock, valued at approximately $11,986,000.

Several other institutional investors also recently modified their holdings of TDACU. Tuttle Capital Management LLC acquired a new stake in shares of Translational Development Acquisition in the 4th quarter valued at approximately $461,000. Calamos Advisors LLC bought a new stake in Translational Development Acquisition in the fourth quarter valued at approximately $6,915,000. Wolverine Asset Management LLC bought a new stake in Translational Development Acquisition in the fourth quarter valued at approximately $5,716,000. MMCAP International Inc. SPC bought a new stake in Translational Development Acquisition in the fourth quarter valued at approximately $6,454,000. Finally, Wealthspring Capital LLC bought a new stake in Translational Development Acquisition in the fourth quarter valued at approximately $1,095,000.

Translational Development Acquisition Stock Down 0.4%

Shares of NASDAQ:TDACU opened at $10.26 on Monday. Translational Development Acquisition Corp. has a 52 week low of $10.00 and a 52 week high of $10.30. The firm has a 50 day moving average price of $10.18.

About Translational Development Acquisition

(Free Report)

Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector.

See Also

Institutional Ownership by Quarter for Translational Development Acquisition (NASDAQ:TDACU)

Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.